StreetInsider.com News Articles

Form 4 Elevance Health, Inc. For: Jul 17 Filed by: PERU RAMIRO G

Fri, 17 Jul 2026 15:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26783905.html

Form 4 Elevance Health, Inc. For: Jul 17 Filed by: PERU RAMIRO G

Fri, 17 Jul 2026 15:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26783905.html

Form 4 Elevance Health, Inc. For: Jul 17 Filed by: BOUDREAUX GAIL

Fri, 17 Jul 2026 13:51:00 -0400

si-local-file:///var/storage/secattach/20260717/26783664.html

Form 4 Elevance Health, Inc. For: Jul 17 Filed by: BOUDREAUX GAIL

Fri, 17 Jul 2026 13:51:00 -0400

si-local-file:///var/storage/secattach/20260717/26783664.html

Elevance (ELV) PT Raised to $395 at Leerink

Fri, 17 Jul 2026 08:36:03 -0400

Leerink analyst Whit Mayo raised the price target on Elevance (NYSE: ELV) to $395.00 (from $364.00) while maintaining a Market Perform rating.

Elevance (ELV) PT Lowered at RBC Capital; 'Solid results but short of elevated expectations'

Thu, 16 Jul 2026 09:23:20 -0400

(Updated - July 16, 2026 9:23 AM EDT)

RBC Capital analyst Ben Hendrix lowered the price target on Elevance (NYSE: ELV) to $424.00 (from $439.00) while maintaining a Sector Perform rating.

The analyst commented: "Solid results but short of elevated expectations; ELV beat 2Q26 expectations, raised full-year adjusted EPS guidance to at least $27.00, and reaffirmed at least 12% EPS growth in 2027. The outsized ~8.5% decline despite a 40-bps MCR beat highlights elevated expectations heading into managed care earnings season. We attribute Wednesday's weakness in large part to persistent Medicaid utilization pressure among the continuing member base and planned market exits

Elevance (ELV) PT Lowered at RBC Capital; 'Solid results but short of elevated expectations'

Thu, 16 Jul 2026 09:23:20 -0400

(Updated - July 16, 2026 9:23 AM EDT)

RBC Capital analyst Ben Hendrix lowered the price target on Elevance (NYSE: ELV) to $424.00 (from $439.00) while maintaining a Sector Perform rating.

Bernstein SocGen on Elevance (ELV): 'ELV announces market exits in Medicaid'

Thu, 16 Jul 2026 08:53:34 -0400

Bernstein SocGen Group analyst Lance Wilkes reiterated an Outperform rating and $482.00 price target on Elevance (NYSE: ELV).

The analyst commented: "ELV announces market exits in Medicaid, this is an important catalyst for Medicaid recovery; Elevance in their 2Q 2026 earnings conference call mentioned that they will be exiting DC Medicaid markets. ELV is also expected to exit additional markets over the next 12 to 18 months where they “do not see path to sustainable performance”. ELV mentioned that they assess the strategic fit, operational requirement, and ability to generate return on capital as measures to decide the exit. Our take

Elevance (ELV) PT Lowered to $473 at Wells Fargo

Thu, 16 Jul 2026 06:56:20 -0400

Wells Fargo analyst Stephen Baxter lowered the price target on Elevance (NYSE: ELV) to $473.00 (from $492.00) while maintaining a Overweight rating.

Elevance (ELV) PT Raised to $393 at Baird

Thu, 16 Jul 2026 06:45:02 -0400

Baird analyst Michael Ha raised the price target on Elevance (NYSE: ELV) to $393.00 (from $331.00) while maintaining a Neutral rating.

Elevance (ELV) PT Raised to $455 at Guggenheim

Thu, 16 Jul 2026 06:41:13 -0400

(Updated - July 16, 2026 6:41 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on Elevance (NYSE: ELV) to $455.00 (from $399.00) while maintaining a Buy rating.

The analyst commented: 'ELV reported 2Q26 operational upside with continued benefits stemming from its reworked MA product/portfolio. HIX also continues to trend favorably, although mgmt is holding that cushion close given the propensity for 2H26 seasonality-related offsets. Brighter Medicaid rates are also showing themselves through, and we see ELV’s posturing around the flexibility to exit states/programs where returns are not viable as a positive development, all-else equal. Against this backdrop, we continue to

Elevance (ELV) PT Raised to $455 at Guggenheim

Thu, 16 Jul 2026 06:41:13 -0400

(Updated - July 16, 2026 6:41 AM EDT)

Guggenheim analyst Jason Cassorla raised the price target on Elevance (NYSE: ELV) to $455.00 (from $399.00) while maintaining a Buy rating.

Elevance (ELV) PT Lowered to $457 at Barclays

Thu, 16 Jul 2026 05:17:35 -0400

Barclays analyst Andrew Mok lowered the price target on Elevance (NYSE: ELV) to $457.00 (from $480.00) while maintaining a Overweight rating.

Form 10-Q Elevance Health, Inc. For: Jun 30

Wed, 15 Jul 2026 11:27:00 -0400

si-local-file:///var/storage/secattach/20260715/26772759.html

Form 10-Q Elevance Health, Inc. For: Jun 30

Wed, 15 Jul 2026 11:27:00 -0400

si-local-file:///var/storage/secattach/20260715/26772759.html

Insurance stocks fall after Elevance Health results show margin pressure

Wed, 15 Jul 2026 06:56:06 -0400

Investing.com -- Elevance Health’s Health Benefits operating profit collapsed in the second quarter of 2026, igniting a broad premarket selloff across the managed-care sector even as the insurer’s headline earnings handily beat estimates and full-year guidance was lifted.

Elevance shares are down 6.7% in premarket trade Thursday after the report showed adjusted operating margin fell to 3.6% from 5.0% year-over-year.

UnitedHealth Group, which reports its own Q2 results Thursday, saw its shares fall 2.7% in premarket trading, with investors bracing that Elevance’s Medicaid margin deterioration may prove sector-wide rather than company-specific.

Molina Healthcare, a pure-play Medicaid insurer, dropped as much as 9% in

Elevance Health beats estimates but shares fall on margin concerns

Wed, 15 Jul 2026 06:29:03 -0400

Investing.com -- Elevance Health Inc. (NYSE: ELV) reported second-quarter results that exceeded analyst expectations, though shares fell 3.9% premarket as investors focused on declining operating margins.

The health insurer posted adjusted earnings per share of $7.45, beating the analyst consensus of $6.21 by $1.24. Revenue reached $49.8 billion, up 0.8% YoY from $49.4 billion and above the $48.63 billion analyst estimate. The company's results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit.

Despite the earnings beat, the company's operating margin fell to 3.5% from 4.9% in the prior year quarter, while the

Form 8-K Elevance Health, Inc. For: Jul 15

Wed, 15 Jul 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260715/26770342.html

Form 8-K Elevance Health, Inc. For: Jul 15

Wed, 15 Jul 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260715/26770342.html

Elevance Health Inc. (ELV) Tops Q2 EPS by 124c, raises guidance

Wed, 15 Jul 2026 06:01:25 -0400

Elevance Health Inc. (NYSE: ELV) reported Q2 EPS of $7.45, $1.24 better than the analyst estimate of $6.21. Revenue for the quarter came in at $49.8 billion versus the consensus estimate of $48.63 billion.

GUIDANCE:

Elevance Health Inc. sees FY2026 EPS of at least $27.00, versus the consensus of $26.91.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

Elevance Health Inc. (ELV) Tops Q2 EPS by 124c, raises guidance

Wed, 15 Jul 2026 06:01:25 -0400

GUIDANCE:

Elevance Health Inc. sees FY2026 EPS of at least $27.00, versus the consensus of $26.91.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

Wed, 15 Jul 2026 06:00:00 -0400

2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025
2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit
FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results
Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions
FY 2026 operating cash flow guidance raised to at least $6.0 billion

INDIANAPOLIS--(BUSINESS WIRE)-- Elevance

Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

Wed, 15 Jul 2026 06:00:00 -0400

2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025
2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit
FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results
Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions
FY 2026 operating cash flow guidance raised to at least $6.0 billion

INDIANAPOLIS--(BUSINESS WIRE)-- Elevance

Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

Wed, 15 Jul 2026 06:00:00 -0400

2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025
2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit
FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results
Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions
FY 2026 operating cash flow guidance raised to at least $6.0 billion

INDIANAPOLIS--(BUSINESS WIRE)-- Elevance

Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

Wed, 15 Jul 2026 06:00:00 -0400

2Q 2026 operating revenue of $49.8 billion, up 0.8% from 2Q 2025
2Q 2026 diluted EPS1 of $6.71 and adjusted diluted EPS2 of $7.45; results were supported by favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit
FY 2026 diluted EPS1 guidance raised to at least $20.10; adjusted diluted EPS2 guidance raised to at least $27.00, reflecting strong second quarter operating results
Accelerating targeted investments in capabilities that lower healthcare costs, simplify the member and provider experience, and strengthen Carelon's integrated solutions
FY 2026 operating cash flow guidance raised to at least $6.0 billion

INDIANAPOLIS--(BUSINESS WIRE)-- Elevance